Description
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, or GLP-1. It shares approximately 94% sequence homology with native human GLP-1 and incorporates structural modifications that increase stability and support prolonged receptor interaction. Its molecular design includes a modified amino acid at position 8 and a fatty acid side chain attached at lysine 26.
Semaglutide peptides are widely studied in controlled research involving GLP-1 receptor signaling, glucose-related pathways, metabolic activity, and cellular responses associated with energy regulation. Researchers may also examine semaglutide stability under different storage, preparation, and experimental conditions because peptide integrity can directly affect reproducibility and analytical results.
Features
- Composition: Synthetic GLP-1 analog
- Sequence Homology: Approximately 94% homologous to human GLP-1
- Molecular Formula: C187H291N45O59
- Molecular Weight: Approximately 4,113.58 g/mol
- Structural Characteristic: Modified peptide with a fatty diacid side chain attached through a spacer
- Research Classification: GLP-1 receptor agonist peptide
- Research Focus: GLP-1 signaling, metabolic pathways, receptor activity, and glucose-related cellular responses
- High-purity semaglutide should be evaluated using batch-specific analytical documentation, such as an available Certificate of Analysis
- Format: Supplied as lyophilized research material
- Recommended Storage: −20 °C unless otherwise specified in batch documentation
Disclaimer: Supplied strictly for laboratory research. Not intended for human or veterinary use, administration, consumption, diagnosis, treatment, or therapeutic purposes.
Reviews
There are no reviews yet.